血管生成素-2在肾脏疾病中的临床与实验研究进展
本文综述血管生成素-2(Angiopoietin-2)在肾脏疾病中的临床与实验研究。其循环水平升高与脓毒症、急性肾损伤(AKI)、糖尿病肾病白蛋白尿及慢性肾脏病(CKD)肾脏结局和心血管并发症相关。实验研究显示其通过VEPTP调控血管稳定性和内皮完整性,是潜在治疗靶点。
要点
- 循环Angiopoietin-2升高与脓毒症及AKI严重程度相关,可作生物标志物。
- 在糖尿病肾病中与白蛋白尿相关,可能成为保护内皮的治疗靶点。
- 在CKD中与肾脏结局和心血管并发症相关,VEPTP调控其双重作用。
核心结论
- 血管生成素-2在肾脏疾病中具有情境依赖的双重作用,是潜在的生物标志物和治疗靶点。
研究设计与样本
- 综述类文章,检索范围未在摘要中明确报告。
主要发现
- 循环血管生成素-2升高与脓毒症和急性肾损伤相关,强调其作为疾病严重程度生物标志物的作用。
- 在糖尿病肾病中,循环血管生成素-2与白蛋白尿相关,白蛋白尿是疾病进展的关键指标。
- 在慢性肾脏病中,循环血管生成素-2升高与肾脏结局和心血管并发症相关。
- 实验研究中血管生成素-2在血管生成和淋巴管生成中起关键作用,影响血管稳定性和内皮完整性。
- 血管生成素-2的激动和拮抗作用受Tie-2磷酸酶VEPTP调控,并参与调节细胞完整性、炎症和内皮通透性。
临床怎么用
- 可将循环血管生成素-2作为脓毒症相关AKI严重程度的生物标志物进行监测。
- 在糖尿病肾病中可探索以血管生成素-2为靶点保护内皮的治疗策略。
- 在CKD管理中关注血管生成素-2水平以评估肾脏结局和心血管并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angiopoietin-2, an important contributor to angiogenesis and vascular remodeling, is increasingly recognized in kidney research. This review explores clinical insights and experimental perspectives on angiopoietin-2 in kidney diseases. Traditionally seen as an antagonist of the Tie-2, which is a receptor tyrosine kinase of endothelial cells and some hematopoietic stem cells, angiopoietin-2 exerts both proangiogenic and antiangiogenic effects, making it a versatile and context-dependent player in kidney pathophysiology. Elevated circulating angiopoietin-2 levels in clinical scenarios are associated with sepsis and acute kidney injury (AKI), emphasizing its role as a biomarker of disease severity. In diabetic kidney disease, circulating angiopoietin-2 correlates with albuminuria, a crucial indicator of disease progression, and may serve as a treatment target in protecting the endothelium. Angiopoietin-2 is implicated in chronic kidney diseases (CKDs), where its elevated circulating levels correlate with kidney outcomes and cardiovascular complications, suggesting its potential impact on kidney function and overall health. In experimental settings, angiopoietin-2 plays a pivotal role in angiogenesis and lymphangiogenesis, influencing vascular stability and endothelial integrity. The context-dependent agonist and antagonist role of angiopoietin-2 is regulated by a Tie-2 phosphatase, vascular endothelial protein tyrosine phosphatase (VEPTP), further underscoring its complexity. Angiopoietin-2 is also involved in regulating cellular integrity, inflammation, and endothelial permeability, making it a promising therapeutic target for conditions characterized by disrupted endothelial junctions and vascular dysfunction. This review provides a comprehensive overview of the diverse roles of angiopoietin-2 in kidney research, offering insights into potential therapeutic targets and advancements in managing kidney diseases.
引用
- Luo AJ, Chang FC, Lin SL, et al. Exploring Angiopoietin-2: Clinical Insights and Experimental Perspectives in Kidney Diseases. Kidney Int Rep. 2024. PMID: 39698365. doi:10.1016/j.ekir.2024.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。